Antiviral Drugs Market Size & Share, by Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors); Indication - (Influenza, HIV, AIDS, Hepatitis, Harper Simplex Virus (HSV), Coronavirus Infection); Type - (Branded, Generic); Age Group - (Pediatric, Adult, Geriatric) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Global Antiviral Drugs Market Highlights Over 2023 - 2033

The global antiviral drugs market is estimated to garner a revenue of USD 70 Billion by the end of 2033 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 52 Billion in the year 2022. The increasing cases of hepatitis B infection and high investment in R&D activities on antiviral drugs across the world are estimated to propel the market growth during the forecast period. As per the World Health Organization, about 296 million people are suffered from chronic hepatitis B infection in 2019.

Get more information on this report:Download Sample PDF

The growing incidence rate of infectious diseases such as herpes simplex virus, hepatitis virus, and influenza. As per the observations, between September to October 2022, nearly 5300 members tested positive for the influenza virus.

Global Antiviral Drugs Market: Growth Drivers and Challenges

Growth Drivers

• Rising Geriatric Population – The rising number of old people across the world and their rising high chances of getting viral infections is estimated to boost the market growth during the forecast period. Old people are susceptible to diseases due to less immune strength which makes them more prone to any disease or infection. As per the World Health Organization, the number of people aged 60 years and above rose from 1 billion in 2020 to 1.4 billion in 2022.

• Increased Cases of COVID – 19 – The number of global COVID cases across the world in 2022 was 625,700,400 as per the estimations.

• Rising Risk of STDs Among Adults – According to the observations, over 1 million sexually transmitted diseases occur each year with an estimated more than 350 new infections.

• Growing Demand for Generic Versions – As per the IMS Health Institute, the healthcare system of the U.S saved USD 2.2 trillion between 2009 to 2019 with the use of generic drugs.

• Rising Vaccinations Against Viral Infections – The COVID-19 vaccine was administered in more than 13 billion doses until 2022.

Challenges

• Increasing Awareness About Preventive Drugs Treatment
• Presence of Generics
• Drug Resistance

The global antiviral drugs market is segmented and analyzed for demand and supply by drug class into DNA polymerases, reverse transcription, protease, and neuraminidase inhibitors. Out of these, reverse transcription is anticipated to hold the largest market size by the end of 2033 on the back of the growing diagnosis and treatment rate of HIV infection and the increasing efficiency of antiviral drugs on viral diseases. In 2021, about 29 million individuals who suffered from HIV received antiretroviral therapy.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.

Global Antiviral Drugs Market Regional Synopsis

Regionally, the global antiviral drugs market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Amongst these markets, the market in North America region is projected to hold the largest market share by the end of 2033 on the back of a growing patient base, the strong foothold of industry key players, increasing approval, and the expected commercialization of new drugs for viral diseases.  In 2022, the number of COVID-19 cases increased by 8% in North America.

Get more information on this report:Download Sample PDF

The global antiviral drugs market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global antiviral drugs market includes the following segments:

Top Featured Companies Dominating the Global Antiviral Drugs Market

• AstraZeneca LP
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis

• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline, Plc
• Bristol Myers Squibb Company
• Abbott Laboratories
• Plough Publishing House
• Merck & Co., Inc
• Johnson & Johnson Services, Inc
• AbbVie Inc.
• Cipla Inc.
• Dr Reddy’s Laboratories Ltd.